Scribe Therapeutics

www.scribetx.comAlameda, United StatesMember of Connectively Wire since
Releases
1
First release
Most recent
Categories
Nasdaq:SCTX

Press releases from Scribe Therapeutics

Tagged nasdaq sctxClear

1 release

  1. Nasdaq:SCTX

    Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

    Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C…